Nov 8-15, 2021 LSX Investival Showcase
Nov 11, 2021, Redeye Life Science Day, Stockholm, Sweden
BioInvent CEO on the benefits of a diversified portfolio. > Link
LSX Nordics Congress, Sep 7, 2021.
Martin Welschof participates in the panel “Nordic Life Sciences, Further Globally Recognised – What’s Next for the Thriving Ecosystem?”
For further information and registration > Link
Pareto Securities’ Healtchare Conference, Sep 1, 2021 > Presentation
BioInvent’s strategy is to leverage its expertise in immunology, cancer biology and antibody biology to develop cancer immunotherapies to improve the quality of life for cancer patients. This is accomplished through collaborations with pharmaceutical companies, academic research groups, networks of clinical specialists and research foundations. The goal is to create value for the Company’s shareholders based on successful drug development and subsequent revenue streams from existing and future commercial partners.
Our tools for successful drug development
In an automated process, we select optimal antibodies for new drug candidates from our own antibody library – one of the largest in the world.
Our unique and patented screening-platform has the advantage of simultaneously identifying disease-associated targets and antibodies that bind to them.